Body

ORLANDO, Fla. — The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

ORLANDO, Fla. — In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells. This comparison allowed researchers to find mutations that only occurred in the cancer cells.

Researchers uncovered incredible complexity in the cancer genomes, but also got a glimpse of new routes toward personalized medicine. The research was presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

ORLANDO, Fla. — Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

In the single largest cancer genomics investigation reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells. This comparison allowed researchers to find mutations that only occurred in the cancer cells.

They uncovered incredible complexity in the cancer genomes, but also got a glimpse of new routes toward personalized medicine. The work was presented at the American Association for Cancer Research 102nd Annual Meeting 2011.

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus (HEV) in human hepatocytes.1

This study also verifies that HEV is a zoonosis (infectious disease that can be transmitted from animals to humans), which has been suggested for a long time.

HEV is a major cause of epidemic and acute sporadic hepatitis in many developing countries. It is also endemic in many industrialized countries, including the United States, European countries and Japan.

Berlin, Germany, Saturday 02 April 2011: Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.1,2

Berlin, Germany, Saturday 02 April 2011: Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimised.1,2,3,4,5,6

HOUSTON - High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

Synthetic HDL nanoparticles loaded with small interfering RNA to silence cancer-promoting genes selectively shrunk or destroyed ovarian cancer tumors in mice, a research team led by scientists from The University of Texas MD Anderson Cancer Center and the University of North Texas Health Science Center reports in the April edition of Neoplasia.

New guidelines, released by the Centers for Disease Control and Prevention (CDC) and the Healthcare Infection Control Practices Advisory Committee (HICPAC) outline steps to eliminate bloodstream infections in patients with intravenous catheters, which are among the most deadly and costly healthcare-associated infections (HAIs).

LA JOLLA, CA—When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

BUFFALO, N.Y. -- A low dose of insulin has been found to suppress the expression in the blood of four precursor proteins involved in the pathogenesis of Alzheimer's disease, according to new clinical research by University at Buffalo endocrinologists. The research, published in March online in the Journal of Clinical Endocrinology and Metabolism, suggests that insulin could have a powerful, new role to play in fighting Alzheimer's disease.

MAYWOOD, Ill. -- An award-winning Loyola University Health System study includes some unexpected findings about the immune systems of smoke-inhalation patients.

Contrary to expectations, patients who died from their injuries had lower inflammatory responses in their lungs than patients who survived.

"Perhaps a better understanding of this early pulmonary immune dysfunction will allow for therapies that further improve outcomes in burn care," researchers reported.

Berlin, Germany, Friday 01 April 2011: Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.1,2

A new study presented today at the International Liver CongressTM shows a novel pathway where activated natural killer (NK) cells expressing death ligands may excessively down-modulate the antiviral immune response in chronic HBV patients.1

Blocking the TNF-related apoptosis-inducing ligand (TRAIL) pathway partially reconstitutes HBV-specific T cells, suggesting that these cells are vulnerable to NK cell-mediated apoptosis through this death ligand pathway.